Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities

J Liu, Q Xiao, J Xiao, C Niu, Y Li, X Zhang… - Signal transduction and …, 2022 - nature.com
The Wnt/β-catenin pathway comprises a family of proteins that play critical roles in
embryonic development and adult tissue homeostasis. The deregulation of Wnt/β-catenin …

All roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase

J Sangodkar, CC Farrington, K McClinch… - The FEBS …, 2016 - Wiley Online Library
Protein phosphatase 2A (PP 2A) is a serine/threonine phosphatase involved in the
regulation of many cellular processes. A confirmed tumor suppressor protein, PP 2A is …

Plasma cell leukemia: definition, presentation, and treatment

MT Gundesen, T Lund, HEH Moeller… - Current oncology …, 2019 - Springer
Abstract Purpose of Review We discuss current topics on the definition of plasma cell
leukemia and the distinction between plasma cell leukemia and multiple myeloma …

Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer

O Kauko, J Westermarck - The international journal of biochemistry & cell …, 2018 - Elsevier
Propagation of transient signals requires coordinated suppression of antagonistic
phosphatase activity. Protein phosphatase 2A (PP2A) is a broad specificity serine/threonine …

PP2A-B55: substrates and regulators in the control of cellular functions

P Amin, S Awal, S Vigneron, S Roque, F Mechali… - Oncogene, 2022 - nature.com
PP2A is a major serine/threonine phosphatase class involved in the regulation of cell
signaling through the removal of protein phosphorylation. This class of phosphatases is …

Tumor suppressive protein phosphatases in human cancer: Emerging targets for therapeutic intervention and tumor stratification

B Meeusen, V Janssens - The international journal of biochemistry & cell …, 2018 - Elsevier
Aberrant protein phosphorylation is one of the hallmarks of cancer cells, and in many cases
a prerequisite to sustain tumor development and progression. Like protein kinases, protein …

Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II …

B Royer, S Minvielle, M Diouf, M Roussel… - Journal of clinical …, 2016 - ascopubs.org
Purpose Primary plasma cell leukemia (pPCL) is a rare and aggressive malignancy with a
poor prognosis. With conventional chemotherapy, patients typically die within 1 year. In all …

[HTML][HTML] Plasma cell leukemia: a review of the molecular classification, diagnosis, and evidenced-based treatment

K Gowin, S Skerget, JJ Keats, J Mikhael, AJ Cowan - Leukemia Research, 2021 - Elsevier
Plasma cell leukemia is a rare and aggressive plasma cell dyscrasia associated with dismal
outcomes. It may arise de novo, primary plasma cell leukemia, or evolve from an antecedent …

Disruption of Runx1 and Runx3 leads to bone marrow failure and leukemia predisposition due to transcriptional and DNA repair defects

CQ Wang, V Krishnan, LS Tay, DWL Chin, CP Koh… - Cell reports, 2014 - cell.com
The RUNX genes encode transcription factors involved in development and human disease.
RUNX1 and RUNX3 are frequently associated with leukemias, yet the basis for their …

The basic biology of PP2A in hematologic cells and malignancies

D Haesen, W Sents, K Lemaire, Y Hoorne… - Frontiers in …, 2014 - frontiersin.org
Reversible protein phosphorylation plays a crucial role in regulating cell signaling. In normal
cells, phosphoregulation is tightly controlled by a network of protein kinases …